Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

· Issued by Phathom Pharmaceuticals, Inc.
Watch Phathom Pharmaceuticals explain itPhathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call · Replay · Jul 30
  • Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo (p